Luminist Capital’s Citius Pharmaceuticals CTXR Stock Holding History

Luminist Capital’s Portfolio CTXR Stock Details CTXR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$263	Buy	+435	New	+$294	﹤0.01%	388
2026 Q1	–	Sell	-435	Closed	-$338	–	132
2025 Q4	$338	Hold	435	–	–	﹤0.01%	262
2025 Q3	$596	Hold	435	–	–	﹤0.01%	308
2025 Q2	$827	Hold	435	–	–	﹤0.01%	296
2025 Q1	$522	Buy	435 +95	+28%	+$227	﹤0.01%	231
2024 Q4	$1.36K	Buy	+340	New	+$2.29K	﹤0.01%	206

Other funds holding CTXR

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

MFS

Miller Financial Services Marshall, Michigan $124M AUM 17.62% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

AAG

Asset Advisory Group Kinnelon, New Jersey $229M AUM

Luminist Capital's CTXR Position: Q2 2026 in Review

Luminist Capital opened a new position in Citius Pharmaceuticals (CTXR) in Q2 2026: 435 shares worth $263. The stake represents ﹤0.01% of the portfolio and ranks #388 among its holdings. This is a return to the name: Luminist Capital previously reported a position in CTXR as recently as Q4 2025.

Luminist Capital first reported a position in CTXR in Q4 2024 and has held it in 6 quarters since. The position peaked at $1.36K in Q4 2024. 43 funds tracked by Wall St. Rank hold CTXR as of Q2 2026.

Luminist Capital held 435 shares of Citius Pharmaceuticals worth $263 as of Q2 2026.
Citius Pharmaceuticals was a new Luminist Capital position in Q2 2026.
Citius Pharmaceuticals made up ﹤0.01% of Luminist Capital's portfolio in Q2 2026, its #388 holding.
Luminist Capital first reported a position in Citius Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
Luminist Capital's Citius Pharmaceuticals position peaked at $1.36K in Q4 2024.
43 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q2 2026.

Based on Luminist Capital's 13F filing for Q2 2026, filed 7 Aug 2026.